Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 227

1.

Lipid-lowering therapy in persons with chronic kidney disease: a systematic review and meta-analysis.

Upadhyay A, Earley A, Lamont JL, Haynes S, Wanner C, Balk EM.

Ann Intern Med. 2012 Aug 21;157(4):251-62. doi: 10.7326/0003-4819-157-4-201208210-00005. Review.

PMID:
22910936
2.

Antioxidants for chronic kidney disease.

Jun M, Venkataraman V, Razavian M, Cooper B, Zoungas S, Ninomiya T, Webster AC, Perkovic V.

Cochrane Database Syst Rev. 2012 Oct 17;10:CD008176. doi: 10.1002/14651858.CD008176.pub2. Review.

PMID:
23076940
3.

Effects of antiplatelet therapy on mortality and cardiovascular and bleeding outcomes in persons with chronic kidney disease: a systematic review and meta-analysis.

Palmer SC, Di Micco L, Razavian M, Craig JC, Perkovic V, Pellegrini F, Copetti M, Graziano G, Tognoni G, Jardine M, Webster A, Nicolucci A, Zoungas S, Strippoli GF.

Ann Intern Med. 2012 Mar 20;156(6):445-59. doi: 10.7326/0003-4819-156-6-201203200-00007. Review.

PMID:
22431677
4.

Effect of statin therapy on cardiovascular and renal outcomes in patients with chronic kidney disease: a systematic review and meta-analysis.

Hou W, Lv J, Perkovic V, Yang L, Zhao N, Jardine MJ, Cass A, Zhang H, Wang H.

Eur Heart J. 2013 Jun;34(24):1807-17. doi: 10.1093/eurheartj/eht065. Epub 2013 Mar 6. Review.

PMID:
23470492
5.

Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis.

Palmer SC, Craig JC, Navaneethan SD, Tonelli M, Pellegrini F, Strippoli GF.

Ann Intern Med. 2012 Aug 21;157(4):263-75. doi: 10.7326/0003-4819-157-4-201208210-00007. Review.

6.

HMG CoA reductase inhibitors (statins) for kidney transplant recipients.

Navaneethan SD, Perkovic V, Johnson DW, Nigwekar SU, Craig JC, Strippoli GF.

Cochrane Database Syst Rev. 2009 Apr 15;(2):CD005019. doi: 10.1002/14651858.CD005019.pub3. Review. Update in: Cochrane Database Syst Rev. 2014;1:CD005019.

PMID:
19370615
7.

Effect of statins on cardiovascular events in patients with mild to moderate chronic kidney disease: a systematic review and meta-analysis of randomized clinical trials.

Zhang X, Xiang C, Zhou YH, Jiang A, Qin YY, He J.

BMC Cardiovasc Disord. 2014 Feb 17;14:19. doi: 10.1186/1471-2261-14-19. Review.

8.

Management of hyperglycemia, dyslipidemia, and albuminuria in patients with diabetes and CKD: a systematic review for a KDOQI clinical practice guideline.

Slinin Y, Ishani A, Rector T, Fitzgerald P, MacDonald R, Tacklind J, Rutks I, Wilt TJ.

Am J Kidney Dis. 2012 Nov;60(5):747-69. doi: 10.1053/j.ajkd.2012.07.017. Epub 2012 Sep 19. Review.

PMID:
22999165
9.

HMG CoA reductase inhibitors (statins) for dialysis patients.

Navaneethan SD, Nigwekar SU, Perkovic V, Johnson DW, Craig JC, Strippoli GF.

Cochrane Database Syst Rev. 2009 Jul 8;(3):CD004289. doi: 10.1002/14651858.CD004289.pub4. Review.

PMID:
19588351
10.

Homocysteine-lowering therapy does not lead to reduction in cardiovascular outcomes in chronic kidney disease patients: a meta-analysis of randomised, controlled trials.

Pan Y, Guo LL, Cai LL, Zhu XJ, Shu JL, Liu XL, Jin HM.

Br J Nutr. 2012 Aug;108(3):400-7. doi: 10.1017/S0007114511007033. Epub 2012 Jan 16. Review.

PMID:
22244447
11.

Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease.

Palmer SC, Navaneethan SD, Craig JC, Johnson DW, Tonelli M, Garg AX, Pellegrini F, Ravani P, Jardine M, Perkovic V, Graziano G, McGee R, Nicolucci A, Tognoni G, Strippoli GF.

Ann Intern Med. 2010 Jul 6;153(1):23-33. doi: 10.7326/0003-4819-153-1-201007060-00252. Epub 2010 Jun 24. Review.

PMID:
20439566
12.

The effect of folic acid based homocysteine lowering on cardiovascular events in people with kidney disease: systematic review and meta-analysis.

Jardine MJ, Kang A, Zoungas S, Navaneethan SD, Ninomiya T, Nigwekar SU, Gallagher MP, Cass A, Strippoli G, Perkovic V.

BMJ. 2012 Jun 13;344:e3533. doi: 10.1136/bmj.e3533. Review.

13.

Effects of fibrates in kidney disease: a systematic review and meta-analysis.

Jun M, Zhu B, Tonelli M, Jardine MJ, Patel A, Neal B, Liyanage T, Keech A, Cass A, Perkovic V.

J Am Coll Cardiol. 2012 Nov 13;60(20):2061-71. doi: 10.1016/j.jacc.2012.07.049. Epub 2012 Oct 17. Review.

14.

Statins decrease all-cause mortality only in CKD patients not requiring dialysis therapy--a meta-analysis of 11 randomized controlled trials involving 21,295 participants.

Barylski M, Nikfar S, Mikhailidis DP, Toth PP, Salari P, Ray KK, Pencina MJ, Rizzo M, Rysz J, Abdollahi M, Nicholls SJ, Banach M; Lipid and Blood Pressure Meta-Analysis Collaboration Group.

Pharmacol Res. 2013 Jun;72:35-44. doi: 10.1016/j.phrs.2013.03.007. Epub 2013 Mar 28.

PMID:
23542730
15.

Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials.

Strippoli GF, Navaneethan SD, Johnson DW, Perkovic V, Pellegrini F, Nicolucci A, Craig JC.

BMJ. 2008 Mar 22;336(7645):645-51. doi: 10.1136/bmj.39472.580984.AE. Epub 2008 Feb 25. Review. Erratum in: BMJ. 2009;339:b2951.

16.

Effects of lipid-lowering therapy on reduction of cardiovascular events in patients with end-stage renal disease requiring hemodialysis.

Marrs JC, Saseen JJ.

Pharmacotherapy. 2010 Aug;30(8):823-9. doi: 10.1592/phco.30.8.823. Review.

PMID:
20653359
17.

Statins and Cardiovascular Primary Prevention in CKD: A Meta-Analysis.

Major RW, Cheung CK, Gray LJ, Brunskill NJ.

Clin J Am Soc Nephrol. 2015 May 7;10(5):732-9. doi: 10.2215/CJN.07460714. Epub 2015 Apr 1. Review.

18.

The effect of interventions to prevent cardiovascular disease in patients with type 2 diabetes mellitus.

Huang ES, Meigs JB, Singer DE.

Am J Med. 2001 Dec 1;111(8):633-42.

PMID:
11755507
20.

Lipid-lowering therapy in chronic kidney disease: is there a role for ezetimibe?

Green D, Panayotova R, Ritchie JP, O'Riordan E, McDonald J.

J Ren Care. 2012 Sep;38(3):138-46. doi: 10.1111/j.1755-6686.2012.00309.x. Epub 2012 May 22. Review.

PMID:
22613701

Supplemental Content

Support Center